Caring Brands, Inc. (NASDAQ:CABR) Short Interest Up 281.9% in August

Caring Brands, Inc. (NASDAQ:CABR) was the target of a significant growth in short interest during the month of August. As of August 31st, there was short interest totaling 23,442 shares, a growth of 281.9% from the August 15th total of 6,138 shares. Based on an average daily volume of 31,051 shares, the days-to-cover ratio is currently 0.8 days. Approximately 0.3% of the company’s stock are short sold.

Caring Brands Stock Up 4.4%

CABR stock opened at $1.19 on Friday. The company has a market cap of $12.34 million and a price-to-earnings ratio of -1.61. Caring Brands has a twelve month low of $0.71 and a twelve month high of $5.35. The business has a 50 day moving average price of $1.37 and a two-hundred day moving average price of $1.18. The company has a quick ratio of 4.93, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Caring Brands (NASDAQ:CABR) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.10) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Caring Brands stock. Susquehanna International Group LLP acquired a new position in shares of Caring Brands, Inc. (NASDAQ:CABR) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 20,771 shares of the company’s stock, valued at approximately $26,000. Susquehanna International Group LLP owned about 0.20% of Caring Brands at the end of the most recent reporting period.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Caring Brands in a research report on Tuesday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Caring Brands currently has a consensus rating of “Sell”.

About Caring Brands

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.